Phase II evaluation of suramin in advanced renal cell carcinoma

Autor:	E. David Crawford, Mario A. Eisenberger, Burton M. Needles, Neel Hammond, Thomas E. Seay, Robert C. Flanigan, Danika Lew, Louis E. Schroder
Rok vydání:	2001
Předmět:	Oncology medicine.medical_specialty Group study business.industry Urology Suramin medicine.disease Fixed dose Regimen Renal cell carcinoma Internal medicine Toxicity Medicine business Renal carcinoma Median survival medicine.drug
Zdroj:	Urologic Oncology: Seminars and Original Investigations. 6:145-148
ISSN:	1078-1439
DOI:	10.1016/s1078-1439(00)00126-5
Popis:	Twenty-two eligible patients with advanced renal carcinoma were treated with suramin utilizing a fixed dose regimen. Therapy was reasonably well tolerated with 3 of 22 patients (14%) developing grade 4 toxicity and 11 of 22 patients (50%) having a maximum toxicity of grade 3. There were no responders; median survival was 10 months. Suramin is not an active agent in advanced renal carcinoma.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::b17c8b4bf14db02d3097d5ce8074664f https://doi.org/10.1016/s1078-1439(00)00126-5 Zobrazit plný text záznamu Full Text from ScienceDirect